AI Article Synopsis
- Most data on chondrosarcoma survival comes from small studies, so a systematic review was conducted to analyze factors affecting survival in 560 patients with intracranial chondrosarcoma.
- The study found that the overall 5-year mortality rate was 11.5%, with a median survival time of 24 months, and higher mortality was linked to higher tumor grade, the mesenchymal subtype, and patients who only had surgical resection.
- The findings provide valuable insights into predicting survival outcomes for patients with this type of brain tumor.
Article Abstract
Most data regarding survival in patients with chondrosarcoma are limited to case studies and small series performed at single institutions. A systematic review was performed to study the relationship between potential prognostic factors and survival. The survival rates were analyzed according to modality of treatment, treatment history, histological subtype, and histological grade. A total of 560 patients with intracranial chondrosarcoma were analyzed. Median follow-up time was 60 months. The 5-year mortality among all patients was 11.5% with median survival of 24 months. Mortality at 5 years was significantly greater for patients with tumors of higher grade, or of the mesenchymal subtype, or who had received surgical resection alone. The results of our systematic review provide useful data in predicting survival among intracranial chondrosarcoma patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795514 | PMC |
| http://dx.doi.org/10.1016/j.jocn.2009.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!